Major Depressive Disorder (MDD) Clinical Trial
Official title:
Effectiveness of Different Intensities Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Randomized Controlled Trial
1. This pilot randomized controlled trial aims at investigating the effects of different intensities of aerobic walking exercise to alleviate depression in older adults with major depressive disorder. Both baseline and post-intervention measurements will be conducted at the Exercise Physiology Laboratory, Division of Kinesiology, School of Public Health, The University of Hong Kong, while the exercise intervention will be conducted outdoors in a small group setting (3-5 participants). 2. Three-time-per-week moderate-intensity (~3.5 METs) or vigorous-intensity (~7 METs) walking exercise will be prescribed to participants in two exercise groups, while the participants in the waitlist group will receive no intervention. The intervention duration is 12 weeks. 3. We will recruit participants from the community in HK. Interested participants will be invited for a semi-structured interview including an assessment on the Beck Depression Inventory and medical history record to confirm eligibility.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00316160 -
Sexual Functioning Study With Antidepressants
|
Phase 4 | |
| Completed |
NCT05416957 -
Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
|
Phase 1 | |
| Active, not recruiting |
NCT03642964 -
A Study in Patients With Major Depressive Disorder
|
Phase 2 | |
| Terminated |
NCT01111565 -
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
| Completed |
NCT01912196 -
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)
|
Phase 2 | |
| Completed |
NCT00958204 -
Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression
|
Phase 3 | |
| Completed |
NCT00102492 -
Study Of GW679769 In Major Depressive Disorder
|
Phase 2 | |
| Completed |
NCT02012218 -
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
|
Phase 3 | |
| Completed |
NCT01477203 -
Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders
|
Phase 4 | |
| Completed |
NCT00768430 -
Optimization of IV Ketamine for Treatment Resistant Depression
|
Phase 2 | |
| Completed |
NCT00559299 -
Patient Tolerability Study of GSK163090
|
Phase 1 | |
| Terminated |
NCT01123707 -
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
| Completed |
NCT05541302 -
Retrospective TMS Therapy for Adults With MDD
|
||
| Completed |
NCT00330616 -
Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan
|
Phase 2 | |
| Recruiting |
NCT03012724 -
Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)
|
N/A | |
| Completed |
NCT02380066 -
Comparison of Anyu Peibo With Placebo in Treatment of MDD
|
Phase 2 | |
| Not yet recruiting |
NCT02395263 -
Comparison of Yuxintine With Placebo in Treatment of MDD
|
Phase 2 | |
| Completed |
NCT01187407 -
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
|
Phase 3 | |
| Completed |
NCT00448292 -
A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder
|
Phase 2 | |
| Completed |
NCT00057239 -
An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
|
Phase 2 |